Raw Materials and Preparations of Moxifloxacin Hydrochloride of Guilin Pharma Approved for Marketing and Passes Consistency Evaluation
The packaging box is for reference only
On November 3, 2021, the raw materials and preparations (strength: 0.4 g) of moxifloxacin hydrochloride produced by Guilin Pharma were approved for marketing, which was deemed to have passed the consistency evaluation.
Moxifloxacin Hydrochloride Tablets is the fourth approved product of Guilin Pharma this year. As per the relevant national policies, drugs that have passed the consistency evaluation (generic drugs approved according to the newly registered classification are deemed to have passed the consistency evaluation) will receive more support in medical insurance payment and medical institution procurement, which will be conducive to expanding the market share of these drugs and enhancing their market competitiveness.
◀ About Guilin Pharma
Guilin pharmaceutical Co.,Ltd. (hereinafter referred to as "Guilin Pharma") is a holding enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharma", stock code: 600196-SH, 02196-HK).
Guilin Pharma is a comprehensive pharmaceutical company engaged in R&D, production and marketing of chemical drugs. At present, it is the largest pharmaceutical export enterprise in Guangxi Zhuang Autonomous Region. The Company has more than 200 types of products, including four main forms such as tablet, capsule, injection and drug substance. Its antimalarial drug Artesun® Artesunate for Injection with independent intellectual property rights has been given the Class I New Drug Certificate No. X-01 of the People's Republic of China. At present, the Company has a total of 24 antimalarial preparation products certified by WHO-PQ, and is the antimalarial drug manufacturer with the most WHO-PQ certifications in the world.
Its Artesun® Artesunate for Injection, an innovator drug in the artesunate series, is used worldwide, saving nearly 100,000 lives (most are African children) each year. Up to now, Guilin Pharma has supplied more than 200 million vials to malaria-affected areas around the world, restoring 40 million severe malaria patients to health.